Brief: 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

89bio

04/12/2023 12:50

Dec 4 (Reuters) - 89Bio Inc  ETNB.O :
    * 89BIO REACHES ALIGNMENT WITH THE FDA AND EMA ON PHASE 3
PROGRAM
FOR PEGOZAFERMIN IN NONALCOHOLIC STEATOHEPATITIS (NASH); PROGRAM
INITIATION PLANNED IN THE FIRST HALF OF 2024
    * 89BIO INC: OUTCOMES TRIAL IN F4 CIRRHOTIC NASH PATIENTS
EXPECTED
TO SUPPORT FULL APPROVAL ACROSS F2-F4 NASH
    * 89BIO INC: NASH TRIALS TO INCLUDE PATIENTS ON BACKGROUND
GLP-1
THERAPY TO ASSESS POTENTIAL OF COMBINATION WITH PEGOZAFERMIN

Source text for Eikon:  ID:nGNX3Ldzdd 
Further company coverage:  ETNB.O 

 ((Reuters.Briefs@thomsonreuters.com;))